Migraine Drugs-Europe Market Status and Trend Report 2013-2023

January 2018 | 139 pages | ID: M48D5ADD20CEN
MIReports Co., Limited

Abstracts

Report Summary

Migraine Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Migraine Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

• Whole Europe and Regional Market Size of Migraine Drugs 2013-2017, and development forecast 2018-2023
• Main market players of Migraine Drugs in Europe, with company and product introduction, position in the Migraine Drugs market
• Market status and development trend of Migraine Drugs by types and applications
• Cost and profit status of Migraine Drugs, and marketing status
• Market growth drivers and challenges

The report segments the Europe Migraine Drugs market as:

Europe Migraine Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia

Europe Migraine Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Sumatriptan
Zolmitriptan
Rizatriptan
Other Drug

Europe Migraine Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Household Use
Others

Europe Migraine Drugs Market: Players Segment Analysis (Company and Product introduction, Migraine Drugs Sales Volume, Revenue, Price and Gross Margin):
Allergan
Merck
Pfizer
Teva
Pfizer
Johnson & Johnson
Endo International
GlaxoSmithKline
Impax
Abbott
Bayer
Eli Lilly
Ethypharm
Kowa Pharmaceuticals America
Winston Pharmaceuticals
AstraZeneca

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF MIGRAINE DRUGS

1.1 Definition of Migraine Drugs in This Report
1.2 Commercial Types of Migraine Drugs
  1.2.1 Sumatriptan
  1.2.2 Zolmitriptan
  1.2.3 Rizatriptan
  1.2.4 Other Drug
1.3 Downstream Application of Migraine Drugs
  1.3.1 Hospitals
  1.3.2 Clinics
  1.3.3 Household Use
  1.3.4 Others
1.4 Development History of Migraine Drugs
1.5 Market Status and Trend of Migraine Drugs 2013-2023
  1.5.1 Europe Migraine Drugs Market Status and Trend 2013-2023
  1.5.2 Regional Migraine Drugs Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Migraine Drugs in Europe 2013-2017
2.2 Consumption Market of Migraine Drugs in Europe by Regions
  2.2.1 Consumption Volume of Migraine Drugs in Europe by Regions
  2.2.2 Revenue of Migraine Drugs in Europe by Regions
2.3 Market Analysis of Migraine Drugs in Europe by Regions
  2.3.1 Market Analysis of Migraine Drugs in Germany 2013-2017
  2.3.2 Market Analysis of Migraine Drugs in United Kingdom 2013-2017
  2.3.3 Market Analysis of Migraine Drugs in France 2013-2017
  2.3.4 Market Analysis of Migraine Drugs in Italy 2013-2017
  2.3.5 Market Analysis of Migraine Drugs in Spain 2013-2017
  2.3.6 Market Analysis of Migraine Drugs in Benelux 2013-2017
  2.3.7 Market Analysis of Migraine Drugs in Russia 2013-2017
2.4 Market Development Forecast of Migraine Drugs in Europe 2018-2023
  2.4.1 Market Development Forecast of Migraine Drugs in Europe 2018-2023
  2.4.2 Market Development Forecast of Migraine Drugs by Regions 2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Europe Market Status by Types
  3.1.1 Consumption Volume of Migraine Drugs in Europe by Types
  3.1.2 Revenue of Migraine Drugs in Europe by Types
3.2 Europe Market Status by Types in Major Countries
  3.2.1 Market Status by Types in Germany
  3.2.2 Market Status by Types in United Kingdom
  3.2.3 Market Status by Types in France
  3.2.4 Market Status by Types in Italy
  3.2.5 Market Status by Types in Spain
  3.2.6 Market Status by Types in Benelux
  3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Migraine Drugs in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Migraine Drugs in Europe by Downstream Industry
4.2 Demand Volume of Migraine Drugs by Downstream Industry in Major Countries
  4.2.1 Demand Volume of Migraine Drugs by Downstream Industry in Germany
  4.2.2 Demand Volume of Migraine Drugs by Downstream Industry in United Kingdom
  4.2.3 Demand Volume of Migraine Drugs by Downstream Industry in France
  4.2.4 Demand Volume of Migraine Drugs by Downstream Industry in Italy
  4.2.5 Demand Volume of Migraine Drugs by Downstream Industry in Spain
  4.2.6 Demand Volume of Migraine Drugs by Downstream Industry in Benelux
  4.2.7 Demand Volume of Migraine Drugs by Downstream Industry in Russia
4.3 Market Forecast of Migraine Drugs in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF MIGRAINE DRUGS

5.1 Europe Economy Situation and Trend Overview
5.2 Migraine Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 MIGRAINE DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

6.1 Sales Volume of Migraine Drugs in Europe by Major Players
6.2 Revenue of Migraine Drugs in Europe by Major Players
6.3 Basic Information of Migraine Drugs by Major Players
  6.3.1 Headquarters Location and Established Time of Migraine Drugs Major Players
  6.3.2 Employees and Revenue Level of Migraine Drugs Major Players
6.4 Market Competition News and Trend
  6.4.1 Merger, Consolidation or Acquisition News
  6.4.2 Investment or Disinvestment News
  6.4.3 New Product Development and Launch

CHAPTER 7 MIGRAINE DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Allergan
  7.1.1 Company profile
  7.1.2 Representative Migraine Drugs Product
  7.1.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Allergan
7.2 Merck
  7.2.1 Company profile
  7.2.2 Representative Migraine Drugs Product
  7.2.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Merck
7.3 Pfizer
  7.3.1 Company profile
  7.3.2 Representative Migraine Drugs Product
  7.3.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.4 Teva
  7.4.1 Company profile
  7.4.2 Representative Migraine Drugs Product
  7.4.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Teva
7.5 Pfizer
  7.5.1 Company profile
  7.5.2 Representative Migraine Drugs Product
  7.5.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.6 Johnson & Johnson
  7.6.1 Company profile
  7.6.2 Representative Migraine Drugs Product
  7.6.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.7 Endo International
  7.7.1 Company profile
  7.7.2 Representative Migraine Drugs Product
  7.7.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Endo International
7.8 GlaxoSmithKline
  7.8.1 Company profile
  7.8.2 Representative Migraine Drugs Product
  7.8.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.9 Impax
  7.9.1 Company profile
  7.9.2 Representative Migraine Drugs Product
  7.9.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Impax
7.10 Abbott
  7.10.1 Company profile
  7.10.2 Representative Migraine Drugs Product
  7.10.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Abbott
7.11 Bayer
  7.11.1 Company profile
  7.11.2 Representative Migraine Drugs Product
  7.11.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Bayer
7.12 Eli Lilly
  7.12.1 Company profile
  7.12.2 Representative Migraine Drugs Product
  7.12.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
7.13 Ethypharm
  7.13.1 Company profile
  7.13.2 Representative Migraine Drugs Product
  7.13.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Ethypharm
7.14 Kowa Pharmaceuticals America
  7.14.1 Company profile
  7.14.2 Representative Migraine Drugs Product
  7.14.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Kowa Pharmaceuticals America
7.15 Winston Pharmaceuticals
  7.15.1 Company profile
  7.15.2 Representative Migraine Drugs Product
  7.15.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Winston Pharmaceuticals
7.16 AstraZeneca

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MIGRAINE DRUGS

8.1 Industry Chain of Migraine Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF MIGRAINE DRUGS

9.1 Cost Structure Analysis of Migraine Drugs
9.2 Raw Materials Cost Analysis of Migraine Drugs
9.3 Labor Cost Analysis of Migraine Drugs
9.4 Manufacturing Expenses Analysis of Migraine Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF MIGRAINE DRUGS

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Reference